Background: Health-related quality of life (HRQOL) questionnaires are increasingly used as outcome measures in research and clinical practice to assess treatment effectiveness in coronary heart disease (CHD) alongside traditional outcome measures. The Coronary Revascularisation Outcome Questionnaire (CROQ) is a patient-reported outcome measure (PROM) to evaluate health outcomes and HRQOL before and after coronary artery bypass grafting surgery (CABG) and percutaneous coronary intervention (PCI). Aim: To translate the CROQ-PCI from English into Norwegian and test its psychometric properties. Methods: Independent forward and backward translation was done following international guidelines. The CROQ was then pretested with both healthcare professionals and patients before the psychometric properties were field tested in a sample of patients who had undergone PCI. Psychometric testing included an evaluation of: acceptability; tests of scaling assumptions; reliability; content validity; construct validity based on within-scale analyses; and construct validity based on comparisons with external measures. Results: 171 of 258 (66%) invited patients participated. The CROQ was acceptable to patients (low proportion of missing data and good response rate), reliable (good internal consistency and test-retest reliability for all scales), had good content validity (reported by both patients and healthcare professionals) and good construct validity (convergent validity with the SF-12 and Seattle Angina Questionnaire, known groups validity and factor analysis).
Introduction
Coronary heart disease (CHD), which includes acute myocardial infarction, acute coronary syndrome and angina pectoris, is one of the major causes of death in Norway and in the rest of the world. In 2014, 20% of all deaths in Europe were due to CHD. 1 Whilst the number of deaths has dramatically decreased in Norway and in western and northern Europe over the last decade, 1 morbidity remains high. Treatments for CHD include medical management and coronary revascularisation (percutaneous coronary intervention (PCI) and coronary artery bypass grafting surgery (CABG)), depending on clinical criteria. 2 PCI has now become one of the most frequently performed therapeutic interventions in medicine. 3 The success of the treatments are traditionally measured by the need for subsequent treatments, complications due to the treatment and/or underlying disease, such as death and myocardial infarction, as well as long term survival. 4 In recent years there has been increasing interest in including measures of health-related quality of life (HRQOL) and patient-reported outcome measures (PROMs) alongside more traditional outcome measures in evaluating clinical treatment effects. 5 These capture the patients' perspective of health, functioning and treatment benefit and complement and extend information on clinical outcomes. PROMs have been reported to be one of the outcomes most important to patients. 6, 7 Although not routinely used across all of clinical practice or clinical trials, data from PROMs are valued by both patients, clinicians and policy makers, and are recommended for use to help reduce the burden of disease and improve well-being following CHD treatments. 7 HRQOL in CHD can be assessed using generic and/or disease specific PROMs. [8] [9] [10] The latter is considered to be more clinically relevant as these are more sensitive to change between severity levels and improvement or deterioration in the disease. 4, 6, 11 In CHD the typical aspects included in HRQOL assessments are symptoms of angina and heart failure, exercise capacity, psychosocial consequences and psychological stress related to the aforementioned symptoms. 10 Whilst there are a number of disease-specific PROMs for CHD, there is only one validated PROM for coronary revascularisation with demonstrated evidence of acceptability, reliability, validity and responsiveness in CABG and PCI samples, the Coronary Revascularisation Outcome Questionnaire (CROQ). 4 The CROQ includes symptoms, physical-, psychosocial-and cognitive-functioning, adverse effects and satisfaction with treatment. Its content was developed based on a literature review, content of existing questionnaires, expert opinions and qualitative interviews with CHD patients. Rigorous psychometric testing has shown that it is an acceptable, reliable, valid and responsive instrument. 4, 12, 13 The original version is in English but it has been translated using international guidelines into several languages. [14] [15] [16] [17] This paper describes the translation and psychometric validation process for developing a Norwegian version of the CROQ-PCI post-revascularisation version using internationally recommended guidelines. 18 
Methods

Sampling and ethics
The study was reviewed and approved by The Regional Committee for Medical and Health Research Ethics and The Data Protection Official for Research at the University Hospital North Norway, Tromsø. We followed the hospital's guidelines on good clinical research practice including how to manage the study and store the data securely. All the participants received written information about the study, and the investigation conformed with the principles outlined in the Declaration of Helsinki. 19 The sample size was based on recommendations for psychometric validation studies. 20 For the psychometric testing sample, patients who had undergone PCI at the University Hospital North Norway were consecutively recruited between August and October 2012. Inclusion criteria were: CHD as the main diagnosis, no other coexisting severe illness (e.g. cancer, dementia), age ≥ 18, living at home and having Norwegian as their first language. A subsample of 22 patients agreed to complete a second questionnaire within 2-3 weeks after returning the first questionnaire to enable an assessment of the reproducibility of the questionnaire (test-retest sample).
For the pretesting of the questionnaire during the translation process six hospitalised patients who had undergone PCI and fulfilled the same inclusion criteria as above were approached before discharge. Those consenting were interviewed regarding the clarity and relevance of the questionnaire content, the phrasing of questions and the time taken to complete the questionnaire.
The Coronary Revascularisation Outcome Questionnaire
The CROQ is a self-administered questionnaire and takes approximately 10 minutes to complete. It has four versions: pre-PCI, pre-CABG, post-PCI and post-CABG. 4 All versions contain four core domains: symptoms (7 items), physical functioning (8 items), psychosocial functioning (14 items) and cognitive functioning (3 items). The two postrevascularisation versions contain two additional scales: satisfaction (6 items) and adverse effects (6 items specific to PCI or 11 items specific to CABG). 4 The items are rated using 3-6-point Likert scales. The items in each domain are summed and the score converted to a 0-100 scale, where 100 is the best possible outcome. Missing responses on items are imputed with the mean score for the scale if the respondent has completed at least half of the items within the scale. The initial version of the CROQ was published in 2004, 4 but it has been revised and revalidated recently. 13 In recent years, the techniques of PCI treatment have evolved and the instrument has been modified to reflect these changes (CROQv2). Nowadays PCI is more often done via the radial artery than the femoral artery. 21 As such the items in version 2 of the CROQ-PCI post-revascularisation adverse effects scale now include treatment via the radial artery as an option. 13 In this study we only translated and validated the CROQ-PCI postrevascularisation (version 2).
The translation procedure. The translation process was conducted by the first and last authors (SAL and TAH) and followed internationally recommended guidelines. 18 The process firstly included a forward translation from English to Norwegian by two independent professional translators. The two different versions were reviewed and a version A was developed and approved by both translators. Version A was then reviewed by a consensus group consisting of cardiologists and nurses, both with and without research experience. When translating to another language the meaning of the questions is particularly important. 18, 22 The consensus group suggested a cultural adaption be made with the words 'playing golf' changed to 'gardening', as the latter is more relevant in Norway. Similar changes have been made to other Norwegian instruments, e.g. the Short Form 36 (SF-36). 23 This discussion resulted in a refined version (Version B) which was then pre-tested with a group of six eligible PCI patients. Patients were asked if the wording was clear and appropriate and if there were any ambiguous questions. The pre-test did not reveal any unclear questions in Version B so two new independent translators translated the questionnaire back into English. The author of the English version of the CROQ received both translations and approved both the back-translated versions. Version B was kept as the final Norwegian version for further testing (see online Appendix).
Field testing
Eligible patients meeting the inclusion criteria as mentioned above were sent questionnaires by postal survey. The information letter providing information about the study and a contact telephone number for the study nurse, and the questionnaire were sent to the patients together with a prepaid return envelope. Completion of the questionnaire was considered as consenting to participate in the study. A reminder was sent to non-responders three weeks after the initial mailing. Those indicating, in a box at the end of the questionnaire, that they were willing to take part in the test-retest study, were sent a second questionnaire after approximately two weeks.
To assess the construct validity of the CROQ, the Seattle Angina Questionnaire (SAQ) and the 12-item short-form health survey (SF-12) were also administered in the questionnaire package as these are widely used in this patient group and include some similar constructs. 8, 9 The SAQ is a disease-specific self-administered questionnaire with 19 items covering the following five domains: 9 physical functioning (9 items), angina frequency (2 items), angina stability (1 item), treatment satisfaction (4 items) and quality of life (3 items). All items in the scales are rated on five-or six-point Likert scales and are summated and converted to a 0-100 scale, with higher scores indicating better quality of life for each of the domains. 24 The SF-12 version 2 is a generic self-administered questionnaire with 12 items covering the following eight domains: 8 physical functioning (2 items), bodily pain (1 item), physical role functioning (2 items), general health (1 item), vitality (1 item), social functioning (1 item), emotional role functioning (2 items) and mental health (2 items). The items are measured on 3-5-point Likert scales and are summated and converted to 0-100 scale, with higher scores indicating better quality of life. The eight domains allow the calculation of two summary scores: the Physical Component Summary score (PCS) and the Mental Component Summary score (MCS). The summary scores incorporate the 1998 US norms into the scoring algorithm and have a mean score of 50 and a standard deviation of 10. 25 In addition to the PROMs, the following sociodemographic and clinical variables were collected from the patients or via the hospital administration system: age, sex, marital status/living arrangements, highest level of education achieved, type of admission (emergency versus elective), treatment access via the radial or femoral artery and whether the patient had previously had heart disease (myocardial infarction, angina pectoris, heart failure or other heart disease).
Psychometric testing and criteria
We assessed the acceptability (response rate, proportion of missing data, floor and ceiling effects), scaling assumptions (item convergent and discriminant validity), reliability (internal consistency and test-retest), construct validity based on within-scale analyses (internal consistency, intercorrelations between scales and factor analysis) and construct validity based on comparisons with external measures (scale convergent and discriminant validity and hypothesis testing) of the translated version. SPSS version 24 was used to analyse the data. Table 1 shows the psychometric tests and criteria applied.
Results
Patient characteristics
During the period from August to October 2012, a total of 356 patients had a PCI procedure at the university hospital, but 98 of these did not meet the above inclusion criteria. Among the 258 invited patients, 171 responded (66%).
The majority of participants were male, living with a partner, emergency admissions and had the PCI procedure done via the radial artery ( Table 2 ). The mean age of respondents was 66.3 (SD 10.7) years and approximately half of the respondents reported no previous heart disease. The mean age for the patients not meeting the inclusion criteria was 67 years and for the non-responders it was 65 years.
Acceptability
All of the items had less than 5% missing data except one of the items in the Symptoms scale related to angina pain radiating to other parts of the body (12% missing data). This item was not identified by patients as difficult to comprehend in the pre-testing of the questionnaire. The proportion of missing data in each of the summated scales was less than 5% indicating good acceptability (Table 3) .
Some of the scales had moderate ceiling effects (Table 3) , with values similar to those in the English version, 4 which is to be expected following successful procedures.
Reliability
Values for Cronbach's alpha coefficient exceeded the criterion value of 0.70 in each of the six scales indicating a high level of internal consistency (Table 3 ). All items exceeded the 0.30 corrected item-total correlation criteria. The value of alpha did not 'substantially' increase if an item was deleted from any of the scales. The intraclass correlation coefficient values exceeded the criterion of 0.70 for all scales in the test-retest subsample (n = 22) indicating a stable and reliable instrument (Table 3) .
Tests of scaling assumptions
The item convergent and discriminant correlations supported the scaling structure of the CROQ (data not shown); 38 of the 44 (86%) items were definite scaling successes and six (14%) were probable scaling successes. None of the items were scaling failures.
Content validity
During the translation process, both content and face validity were assessed and considered to be good by two Evidence that scales differentiate known groups; assessed by comparing CROQ scores between groups hypothesised to differ, e.g. in patients with and without previous heart disease • • CROQ scores should be significantly different for groups expected to differ (p < .05) 20 Table adapted from Schroter and Lamping. 4 consensus groups (nurses and cardiologists) and the pretest sample of CHD patients who had undergone PCI. They looked at the CROQ content overall and the phrasing of the individual questions. The patients reported it was easy to understand and the questions were relevant and unambiguous. Based on the pre-test some of the wording was slightly modified, for example the activity 'playing golf' was changed to 'gardening', as this is more culturally relevant to the Norwegian population.
Construct validity (within scale analyses)
Three types of analyses were conducted to evaluate the CROQ's internal construct validity: internal consistency, intercorrelations between scales and factor analysis. Evidence confirmed the division of items into scales and that the scales measure what they intend to measure.
Internal consistency.
A high level of internal consistency for each scale indicated that a single construct is being measured by each scale and that items can be combined into the scales.
Intercorrelations between scales.
Moderate intercorrelations between the scales indicated that the scales measure related but separate domains. There was evidence of unique reliable variance, indicated by reliability coefficients with values greater than the intercorrelations between scales.
Factor analysis. Rotated principal axis factor analysis with Varimax rotation further confirmed the scaling structure, i.e. that items are correctly grouped together, that items in the same scale measure the same construct and that items in different scales measure different constructs (data not reported). Tests of sampling adequacy (Kaiser-Meyer-Olkin) and sphericity (Bartlett's test of sphericity) were acceptable. All items within a particular scale loaded >.35 on the same scale. Three items loaded higher on the wrong factor, but these could all be explained conceptually. For example, the shortness of breath item loaded higher on the physical functioning scale reflecting the fact that symptoms are induced on exertion. Six items cross loaded onto another factor with a difference of <.20. This pattern of results was similar to the English version.
Construct validity (comparison with external criteria)
Convergent and discriminant validity. Construct validity was also evaluated by examining the relationship between the CROQ and the SF-12, the SAQ and demographic variables (age and sex). Scale scores were moderately to highly correlated with independent measures of the same domain (convergent validity), and less highly correlated with measures of unrelated constructs (discriminant validity) ( Table 4 ). The highest correlation was between the physical functioning scale in the CROQ and the two physical scales in the SAQ and the SF-12. The cognitive functioning and psychosocial functioning CROQ scales were moderately correlated to both the Physical and Mental Component Summary scores on the SF-12 and the SAQ physical function scale, but this result is not particular to the Norwegian version and reflects the fact that mental and physical health in CAD are inextricably linked. As hypothesised, CROQ scale scores were poorly correlated with age and sex (discriminant validity).
Hypothesis testing (analyses against external criteria).
Construct validity was also evaluated by testing hypotheses of differences between groups expected to differ according to an external criterion. Patients with previously known heart disease prior to the PCI scored significantly lower on four of the six CROQ scales than those without previous known heart disease (p < .05). Scales measuring physical health on the CROQ, SF-12 and SAQ were significantly different between the groups; whereas scales measuring mental health were not significantly different across all the HRQOL instruments. Based on these results the CROQ discriminates as well as the SF-12 and the SAQ (Table 5 ).
Discussion
Following international guidelines for translation, cultural adaptation and validation of HRQOL measures, we have shown that the Norwegian CROQ-PCI post-revascularisation version is both acceptable to patients and has good psychometric properties. Whilst there are already several Norwegian translations of CHD-specific HRQOL instruments, none of these instruments were developed specifically for patients undergoing coronary revascularisation. The CROQ captures the patients' perspective both before and after PCI and as such gives us important information regarding symptoms, HRQOL, treatment satisfaction and adverse effects, to use both in clinical practice and research. The response rate of 66% and the low proportion of missing data indicate that the Norwegian version is acceptable to patients. High intra-rater reliability shows that the responses are reproducible and not affected by random error. The scales are also internally consistent and measure separate but related constructs with Cronbach's alpha exceeding the criterion of 0.70 for all the scales. 28 Our results are similar with those of the original English version of the CROQ. 4, 12 When analysing the translated instrument's psychometric properties we assessed the validity in several ways to ensure it was appropriate for the CHD patient group and their treatment. To assess construct validity we choose the same HRQOL instruments as the authors used in the development of the CROQ, although we used the shortened version and summated scales in the SF-12 to reduce patient burden. Our results were similar to those of the original UK version and to other translated versions of the CROQ. 4, [14] [15] [16] [17] In concordance with previous studies, this study also showed the expected pattern of correlations between similar constructs. For example, the symptoms scale in the CROQ correlated with all the other scales on the SF-12 and SAQ. Not unexpectedly it correlated highest with the angina frequency scale in the SAQ, as the level of angina is correlated directly with symptom burden.
It is important for HRQOL instruments to be able to demonstrate a difference between groups where a difference is expected. In this study the patients were divided into two groups: those with or without previous known heart disease preceding the PCI. Earlier studies have shown that patients with known heart disease tend to report lower HRQOL than patients without previous known disease. 13 In this study the patients with known heart disease scored significantly lower on four of the six CROQ scales. The CROQ's satisfaction scale which includes questions about rehabilitation, treatment results and how the patients' consider their heart disease now compared with before the PCI showed a significant difference between the groups. This finding is similar to those reported in a review where the association between poorer health and lower scores on patient satisfaction were described. 32 The Physical Component Summary score in the SF-12 showed a significant difference between the groups, but the Mental Component Summary score did not. In the SAQ, the angina stability scale and the scale for quality of life did not show a significant difference between the two groups. Our comparison of the three instruments shows that the CROQ seems to discriminate at least as well as the other two instruments when comparing groups with and without self-reported previous heart disease.
We only evaluated the psychometric properties of the Norwegian post-PCI version in a sample of post-revascularisation patients. Whilst the pre-PCI version contains all of the same items as the post-PCI version, except those in the satisfaction and adverse effects scales, psychometric testing of these items with a Norwegian sample of patients before they have undergone PCI is recommended. The instrument's responsiveness should also be tested in a study where patients complete questionnaires before and after PCI.
Further work should evaluate the psychometric properties of Norwegian translations of the pre-and post-revascularisation versions of the CROQ-CABG. This would involve forward-backward translation of the post-CABG adverse effects items and independent psychometric testing of the CABG-pre and CABG-post versions in samples of pre-and post-revascularisation CABG patients.
Conclusion
After translation and cultural adaptation following international guidelines and psychometric testing we have demonstrated that the Norwegian version of the CROQ-PCI post-revascularisation version is acceptable, reliable and valid. Further testing of its responsiveness and ability to detect change is needed before recommending its use in clinical practice and research. The availability of several language versions of the CROQ will enable international comparisons. 
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